Granite Bio AG

Granite Bio AG is a clinical-stage immunology company developing first-in-class antibodies targeting the root causes of inflammatory, autoimmune, and fibrotic conditions. Their pipeline includes two lead molecules, GRT-001 and GRT-002, addressing large market opportunities in autoimmune diseases. The company's innovative approach focuses on addressing fundamental disease drivers.

Buy Funded Startups lists

Funding Round: Series B

Funding Amount: $100M

Date: 24-Apr-2025

Investors: Forbion, Sanofi Ventures

Markets: Immunology, Biotechnology

HQ: Basel, Switzerland

Founded: 2021

Website: https://www.granitebio.com/

LinkedIn: https://www.linkedin.com/company/granitebio

Twitter:

Instagram: